Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

▎药明康德内容团队编辑2.15亿美元助力下一代肥胖和代谢疾病疗法开发Metsera公司今日宣布完成2.15亿美元的B轮融资。获得资金将用于加速其下一代肥胖和代谢疾病治疗药物的开发。该公司正在开展超长效、注射型GLP-1受体激动剂的2期临床试验。Met ...

a combination of long-acting amylin analog cagrilintide and GLP-1 agonist semaglutide. The Big Pharma is currently testing ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...

Metsera has raised over $500 million to date. Highly competitive, clinical-stage portfolio accelerating Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway Metsera recently ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...